Senior Vice President, Finance

General Counsel

Chief Operating Officer

Chief Executive Officer

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Institution	Shares	Value	Change
FMR LLC	7,431,403	$365M	INCREASED
Venrock Adviser, LLC	4,148,428	$203M	UNCHANGED
Fairmount Funds Management LLC	3,705,262	$182M	UNCHANGED
BlackRock, Inc.	3,527,087	$173M	DECREASED
VIKING GLOBAL INVESTORS LP	2,666,690	$131M	UNCHANGED

Insider	Type	Shares	Value	Date
Arjun Agarwal (Senior Vice President, Finance)	SELL	699	$57K	2026-06-22
Arjun Agarwal (Senior Vice President, Finance)	SELL	888	$71K	2026-06-22
Paul T Quinlan (General Counsel)	SELL	733	$51K	2026-06-15
Laura Lee Sandler (Chief Operating Officer)	SELL	600	$42K	2026-06-15
Lawrence Otto Klein (Chief Executive Officer)	SELL	1,729	$120K	2026-06-15

Oruka Therapeutics, Inc. Common Stock (ORKA) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades